2026 Q1 -tulosraportti
53 päivää sitten
‧51 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 29.7. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
6 min sittenThe National Healthcare Security Administration just released its preliminary approval list, and the Cervical Photodynamic Therapy System, XIRVIT, is included, which is a good start. Optimistically, it’s highly likely that XIRVIT 1702 will be included in the national medical insurance program this year, leading to rapid sales growth. Coupled with its commercial approval in Europe next year, I’m optimistic that XIRVIT 1702 will push Asiaray’s market capitalization to 20 billion next year. After that, we’ll have to see how other pipeline products perform. https://guba.eastmoney.com/news,688176,1734274781.html 10
·3 päivää sittenRegardless of Cevira's degree of success, one can only pray, wish, and hope that Asieris' willingness to pay is present for royalties. It was not exactly overwhelming for milestones. And what the agreement actually entails, no one knows. Hopefully, Pho themselves know what they have done, but I am not sure.
I doubt there's a lack of willingness to pay to Asieris. The agreement on milestones was unfortunately not clear enough, but hopefully it will resolve itself eventually. As for the royalty agreement, we probably know the most important part. But it certainly wouldn't have hurt if PHO could inform us about the agreement in its entirety. But it is what it is, PHO has never impressed when it comes to information and shareholder friendliness.
·25.6.Odd, isn't it - when the price goes weakly there are plenty of negative posts. When the price goes up, most are positive - so then it might quickly be smart to buy when the sentiment is bad?? For my part, I strongly believe in Cevira, but of course, it also takes some time.Never seen approval of a possible blockbuster come to market and have such a pace with rollout and quick adoption by patients here. Partner Asieris must be close to a world record ;) ? Partner believes this is blockbuster potential in addition.- ·24.6. · MuokattuLove the bearish sentiment! It's so typical that it turns right up then. Especially when someone mentions the probability. GF in a couple of days and several growth initiatives have been established that can provide a foundation for top-line growth and bottom-line growth. For example, Ipsen costs will be significantly reduced in 2027, this provides increased bottom line all else being equal. Briarwood as the largest owner obviously has a plan with the latest initiatives.
·23.6.I'm not going to "baisse" but the probability of seeing the 40s is greater than a comeback to the 70s. PHO reminds me of a wild salmon that unfortunately has jumped ashore. It's still flailing and showing signs of life, but lacks both direction and momentum. Even if good sales figures for Cevira come from Asieris, it will just flail and flail. Hopeless!
@h3nk1 How do you calculate a 2-3 bagger from today's price ? How much Cevira needs to be sold and how large revenues for PHO are needed to justify 3-4 billion in market cap
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
53 päivää sitten
‧51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 6 min sittenThe National Healthcare Security Administration just released its preliminary approval list, and the Cervical Photodynamic Therapy System, XIRVIT, is included, which is a good start. Optimistically, it’s highly likely that XIRVIT 1702 will be included in the national medical insurance program this year, leading to rapid sales growth. Coupled with its commercial approval in Europe next year, I’m optimistic that XIRVIT 1702 will push Asiaray’s market capitalization to 20 billion next year. After that, we’ll have to see how other pipeline products perform. https://guba.eastmoney.com/news,688176,1734274781.html 10
- ·3 päivää sittenRegardless of Cevira's degree of success, one can only pray, wish, and hope that Asieris' willingness to pay is present for royalties. It was not exactly overwhelming for milestones. And what the agreement actually entails, no one knows. Hopefully, Pho themselves know what they have done, but I am not sure.I doubt there's a lack of willingness to pay to Asieris. The agreement on milestones was unfortunately not clear enough, but hopefully it will resolve itself eventually. As for the royalty agreement, we probably know the most important part. But it certainly wouldn't have hurt if PHO could inform us about the agreement in its entirety. But it is what it is, PHO has never impressed when it comes to information and shareholder friendliness.
- ·25.6.Odd, isn't it - when the price goes weakly there are plenty of negative posts. When the price goes up, most are positive - so then it might quickly be smart to buy when the sentiment is bad?? For my part, I strongly believe in Cevira, but of course, it also takes some time.Never seen approval of a possible blockbuster come to market and have such a pace with rollout and quick adoption by patients here. Partner Asieris must be close to a world record ;) ? Partner believes this is blockbuster potential in addition.
- ·24.6. · MuokattuLove the bearish sentiment! It's so typical that it turns right up then. Especially when someone mentions the probability. GF in a couple of days and several growth initiatives have been established that can provide a foundation for top-line growth and bottom-line growth. For example, Ipsen costs will be significantly reduced in 2027, this provides increased bottom line all else being equal. Briarwood as the largest owner obviously has a plan with the latest initiatives.
- ·23.6.I'm not going to "baisse" but the probability of seeing the 40s is greater than a comeback to the 70s. PHO reminds me of a wild salmon that unfortunately has jumped ashore. It's still flailing and showing signs of life, but lacks both direction and momentum. Even if good sales figures for Cevira come from Asieris, it will just flail and flail. Hopeless!@h3nk1 How do you calculate a 2-3 bagger from today's price ? How much Cevira needs to be sold and how large revenues for PHO are needed to justify 3-4 billion in market cap
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 29.7. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
53 päivää sitten
‧51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 29.7. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 6 min sittenThe National Healthcare Security Administration just released its preliminary approval list, and the Cervical Photodynamic Therapy System, XIRVIT, is included, which is a good start. Optimistically, it’s highly likely that XIRVIT 1702 will be included in the national medical insurance program this year, leading to rapid sales growth. Coupled with its commercial approval in Europe next year, I’m optimistic that XIRVIT 1702 will push Asiaray’s market capitalization to 20 billion next year. After that, we’ll have to see how other pipeline products perform. https://guba.eastmoney.com/news,688176,1734274781.html 10
- ·3 päivää sittenRegardless of Cevira's degree of success, one can only pray, wish, and hope that Asieris' willingness to pay is present for royalties. It was not exactly overwhelming for milestones. And what the agreement actually entails, no one knows. Hopefully, Pho themselves know what they have done, but I am not sure.I doubt there's a lack of willingness to pay to Asieris. The agreement on milestones was unfortunately not clear enough, but hopefully it will resolve itself eventually. As for the royalty agreement, we probably know the most important part. But it certainly wouldn't have hurt if PHO could inform us about the agreement in its entirety. But it is what it is, PHO has never impressed when it comes to information and shareholder friendliness.
- ·25.6.Odd, isn't it - when the price goes weakly there are plenty of negative posts. When the price goes up, most are positive - so then it might quickly be smart to buy when the sentiment is bad?? For my part, I strongly believe in Cevira, but of course, it also takes some time.Never seen approval of a possible blockbuster come to market and have such a pace with rollout and quick adoption by patients here. Partner Asieris must be close to a world record ;) ? Partner believes this is blockbuster potential in addition.
- ·24.6. · MuokattuLove the bearish sentiment! It's so typical that it turns right up then. Especially when someone mentions the probability. GF in a couple of days and several growth initiatives have been established that can provide a foundation for top-line growth and bottom-line growth. For example, Ipsen costs will be significantly reduced in 2027, this provides increased bottom line all else being equal. Briarwood as the largest owner obviously has a plan with the latest initiatives.
- ·23.6.I'm not going to "baisse" but the probability of seeing the 40s is greater than a comeback to the 70s. PHO reminds me of a wild salmon that unfortunately has jumped ashore. It's still flailing and showing signs of life, but lacks both direction and momentum. Even if good sales figures for Cevira come from Asieris, it will just flail and flail. Hopeless!@h3nk1 How do you calculate a 2-3 bagger from today's price ? How much Cevira needs to be sold and how large revenues for PHO are needed to justify 3-4 billion in market cap
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt